Anhui Wanbang Pharmaceutical Technology Co.,Ltd. (SHE:301520)
China · Delayed Price · Currency is CNY 69.33
+1.52 (2.24%)
At close: Oct 9, 2026
SHE:301520 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 212.43 | 270.42 | 371.69 | 317.16 | 246.21 | 200.44 |
Other Revenue | 2.67 | 3.76 | 7.41 | 24.65 | 14.57 | 10.65 |
| 215.1 | 274.18 | 379.09 | 341.81 | 260.78 | 211.09 | |
Revenue Growth | -36.49% | -27.67% | 10.91% | 31.07% | 23.54% | 51.72% |
Cost of Revenue | 178.94 | 203.17 | 229.05 | 174.53 | 129.39 | 99.82 |
Gross Profit | 36.16 | 71.01 | 150.04 | 167.27 | 131.39 | 111.27 |
Selling, General & Admin | 28.14 | 28.43 | 31.77 | 25.21 | 16.97 | 15.37 |
Research & Development | 24.68 | 32.93 | 60.68 | 34.52 | 15.97 | 10.35 |
Other Operating Expenses | 2.71 | -0.05 | 0.36 | 0.51 | 0.16 | 0.82 |
Operating Expenses | 63.14 | 68.19 | 98.5 | 64.21 | 35.39 | 28.23 |
Operating Income | -26.98 | 2.82 | 51.54 | 103.06 | 95.99 | 83.04 |
Interest Expense | - | - | - | -0 | -0 | -0.01 |
Interest & Investment Income | 18.74 | 13.96 | 24.33 | 7.06 | 4.08 | 2.29 |
Other Non Operating Income (Expenses) | -0.13 | -0.27 | -0.16 | -0.16 | -0.01 | -0.06 |
EBT Excluding Unusual Items | -8.37 | 16.51 | 75.71 | 109.97 | 100.06 | 85.26 |
Gain (Loss) on Sale of Investments | 15.17 | 18.98 | 7.03 | 3.79 | - | - |
Gain (Loss) on Sale of Assets | -0.55 | -0.54 | -0.02 | - | - | - |
Asset Writedown | - | - | - | -0.02 | - | -0 |
Other Unusual Items | 1.24 | 0.9 | 6.77 | 5.91 | 11.09 | 9.07 |
Pretax Income | 7.49 | 35.85 | 89.5 | 119.64 | 111.15 | 94.33 |
Income Tax Expense | -2.27 | -0.58 | 3.97 | 11.55 | 12.41 | 12.46 |
Earnings From Continuing Operations | 9.76 | 36.43 | 85.53 | 108.09 | 98.73 | 81.87 |
Net Income | 9.76 | 36.43 | 85.53 | 108.09 | 98.73 | 81.87 |
Net Income to Common | 9.76 | 36.43 | 85.53 | 108.09 | 98.73 | 81.87 |
Net Income Growth | -82.97% | -57.40% | -20.87% | 9.48% | 20.60% | 50.18% |
Shares Outstanding (Basic) | 92 | 93 | 94 | 76 | 70 | 70 |
Shares Outstanding (Diluted) | 92 | 93 | 94 | 76 | 70 | 70 |
Shares Change | -2.39% | -0.87% | 23.64% | 7.83% | 0.40% | 4.40% |
EPS (Basic) | 0.11 | 0.39 | 0.91 | 1.43 | 1.41 | 1.17 |
EPS (Diluted) | 0.11 | 0.39 | 0.91 | 1.43 | 1.41 | 1.17 |
EPS Growth | -82.55% | -57.03% | -36.00% | 1.53% | 20.12% | 43.85% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -31.61 | -27.14 | 5.02 | -14.05 | 21.63 | 39.84 |
Free Cash Flow Per Share | -0.34 | -0.29 | 0.05 | -0.19 | 0.31 | 0.57 |
Dividend Per Share | 0.214 | 0.214 | 0.250 | 0.357 | - | - |
Dividend Growth | - | -14.28% | -29.99% | - | - | - |
Gross Margin | 16.81% | 25.90% | 39.58% | 48.94% | 50.38% | 52.71% |
Operating Margin | -12.54% | 1.03% | 13.59% | 30.15% | 36.81% | 39.34% |
Profit Margin | 4.54% | 13.29% | 22.56% | 31.62% | 37.86% | 38.78% |
Free Cash Flow Margin | -14.70% | -9.90% | 1.32% | -4.11% | 8.29% | 18.87% |
EBITDA | -11.55 | 18.51 | 66.66 | 112.72 | 101.36 | 86.96 |
EBITDA Margin | -5.37% | 6.75% | 17.58% | 32.98% | 38.87% | 41.19% |
D&A For EBITDA | 15.42 | 15.69 | 15.12 | 9.66 | 5.37 | 3.92 |
EBIT | -26.98 | 2.82 | 51.54 | 103.06 | 95.99 | 83.04 |
EBIT Margin | -12.54% | 1.03% | 13.59% | 30.15% | 36.81% | 39.34% |
Effective Tax Rate | - | - | 4.43% | 9.66% | 11.17% | 13.21% |
Revenue as Reported | 215.1 | 274.18 | 379.09 | 341.81 | 260.78 | 211.09 |
Advertising Expenses | - | 0.75 | 0.56 | 0.91 | 1.62 | 1.65 |